Such effect would potentially avoid the risk for high toxicity of complete AKT inactivation and would not affect non-malignant cells that typically do not display high FOXM1 levels, while still providing anti-cancer effects of the AKT activity suppression. The gene discussed is AKT1; the disease is cancer.